Next Article in Journal
Passive Coagulability Assay Based on Coherence-Gated Light Scattering
Next Article in Special Issue
The Management of Hematologic Patients with Bloodstream Infections Due to Multi-Drug Resistant Bacteria: Where Do We Stand? From Antibacterial Prophylaxis to the Treatment of Septic Shock
Previous Article in Journal
Change of Title: Bloods Becomes Hemato
Previous Article in Special Issue
Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1
Review

The Next Step for MRD in Myeloma? Treating MRD Relapse after First Line Treatment in the REMNANT Study

1
Department of Hematology, Oslo Myeloma Center, Oslo University Hospital, 0450 Oslo, Norway
2
KG Jebsen Center for B Cell Malignancies, University of Oslo, 0450 Oslo, Norway
*
Author to whom correspondence should be addressed.
Received: 14 August 2020 / Revised: 15 September 2020 / Accepted: 18 September 2020 / Published: 24 September 2020
(This article belongs to the Collection Exclusive Papers of the Editorial Board Members (EBMs) of Hemato)
The treatment approach for multiple myeloma (MM) has changed in recent years. After the approval of maintenance treatment after stem cell transplant in younger patients, the paradigm of continuous treatment is now prevailing in all clinical situations of myeloma. However, the best time to initiate relapse treatment is still unclear. With increased frequency of minimal residual disease (MRD) negativity, and the established clinical benefit of this finding, one of the large clinical questions in myeloma is how to approach MRD re-appearance. In this paper, we go through the MRD technology, existing and possible uses of MRD in the clinic, and data for early treatment before we introduce the design of the ongoing REMNANT study; a randomized study with early treatment of MRD relapse after first line treatment. View Full-Text
Keywords: MRD; VRd; multiple myeloma; early relapse treatment MRD; VRd; multiple myeloma; early relapse treatment
Show Figures

Figure 1

MDPI and ACS Style

Rasmussen, A.-M.; Askeland, F.B.; Schjesvold, F. The Next Step for MRD in Myeloma? Treating MRD Relapse after First Line Treatment in the REMNANT Study. Hemato 2020, 1, 36-48. https://0-doi-org.brum.beds.ac.uk/10.3390/hemato1020008

AMA Style

Rasmussen A-M, Askeland FB, Schjesvold F. The Next Step for MRD in Myeloma? Treating MRD Relapse after First Line Treatment in the REMNANT Study. Hemato. 2020; 1(2):36-48. https://0-doi-org.brum.beds.ac.uk/10.3390/hemato1020008

Chicago/Turabian Style

Rasmussen, Anne-Marie, Frida B. Askeland, and Fredrik Schjesvold. 2020. "The Next Step for MRD in Myeloma? Treating MRD Relapse after First Line Treatment in the REMNANT Study" Hemato 1, no. 2: 36-48. https://0-doi-org.brum.beds.ac.uk/10.3390/hemato1020008

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop